Author: Ahanchian, Hamid; Jones, Carmen M; Chen, Yueh-sheng; Sly, Peter D
Title: Respiratory viral infections in children with asthma: do they matter and can we prevent them? Document date: 2012_9_13
ID: 0mnsm6s4_58
Snippet: Maternally-derived RSV neutralizing antibodies help to protect infants against RSV hospitalization [185] . Palivizumab, a humanised monoclonal antibody against the RSV fusion protein is effective against RSV and wheezing in children and reduces hospitalization in high-risk individuals [185, 187] . RSV prophylaxis with palivizumab significantly reduced the relative risk of subsequent recurrent wheezing in nonatopic premature infants [40] . Motaviz.....
Document: Maternally-derived RSV neutralizing antibodies help to protect infants against RSV hospitalization [185] . Palivizumab, a humanised monoclonal antibody against the RSV fusion protein is effective against RSV and wheezing in children and reduces hospitalization in high-risk individuals [185, 187] . RSV prophylaxis with palivizumab significantly reduced the relative risk of subsequent recurrent wheezing in nonatopic premature infants [40] . Motavizumab is another monoclonal antibody against RSV, with an approximately 20-fold increase in ability to neutralize RSV and 100 fold increase in ability to reduce viral titers compared to palivizumab [188, 189] . Motavizumab was also found to be superior to palivizumab in reducing outpatient medically attended lower respiratory illness by 50% [190] .
Search related documents:
Co phrase search for related documents- approximately increase and high risk: 1
- approximately increase and neutralizing antibody: 1, 2
- approximately increase and relative risk: 1, 2
- approximately increase and respiratory illness: 1
- fold increase and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- fold increase and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- fold increase and neutralizing antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- fold increase and relative risk: 1, 2, 3, 4, 5, 6, 7, 8
- fold increase and respiratory illness: 1, 2
- high risk and low respiratory illness: 1, 2, 3
- high risk and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- high risk and neutralizing antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- high risk and outpatient reduce: 1, 2, 3, 4, 5, 6, 7
- high risk and palivizumab prophylaxis: 1, 2, 3, 4, 5
- high risk and premature infant: 1
- high risk and relative risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- high risk and respiratory illness: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- high risk individual and neutralizing antibody: 1
- high risk individual and respiratory illness: 1
Co phrase search for related documents, hyperlinks ordered by date